Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?
Madhav V Dhodapkar* and Dennis L Cooper
Correspondence *Department Hematology and Hematologic Malignancies, Yale Cancer Center, 333 Cedar Street, PO Box 208021, New Haven, CT 06520, USA
Email madhav.dhodapkar@yale.edu
This article has no abstract so we have provided the first paragraph of the full text.
Almost a decade ago, thalidomide was shown to be clinically active in patients with relapsed and refractory multiple myeloma.1 Combinations of thalidomide with dexamethasone or chemotherapy have now been tested in patients with newly diagnosed myeloma and have been shown to improve response rates. Thalidomide therapy can, however, be associated with potentially disabling adverse events, such as peripheral neuropathy, which may limit its long-term use.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.